Egypt. J. Chem. **Vol. 68,** SI: Z. M. Nofal, pp. 607 - 617 (2025)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

Effect of Lipids and Obesity on Blood Glucose Level: The Connection between Obesity and Diabetes-A Review

Mohammed Nasir Almulhim[1], Hani Saud Almutairi[1], Mohammed Abdulrahman Almashan[1],Soliman Mohammed Alchaidib*[2], Omar Obaid Alharbi[2], MaysamTaysir Almegbel[2], Amani Ayyadhah Alanazi[2], Bander Batti Alrasheedi[2], Ahlam Mohammed Alzahrani[2], Nasser Ali Alhabib[2], Mohammed Ahmed Almansour[2], Mohammed Abdulaziz Almaniea[2], Sultan Abdullah Alsubaie[2], HanadiNaji Alhajrasi[2], Najlaa Saeed Alghamdi[2], WessamAyed Aljohani[2], Mohammed Abdullah Ali Al Nosyan[2], Mohammed Saleh Abdulkareem Al Juma[2], Ahmed Abdullah Sharkh Alsharekh[2]

[1] General Administration of medical services, Riyadh, Saudi Arabia

[2] National Guard Health Affairs, Jeddah, Saudi Arabia

Abstract

Background: Obesity is a primary modifiable risk factor for type 2 diabetes (T2D), driven by pathophysiological mechanisms like insulin resistance and β-cell dysfunction. The global rise in obesity has correspondingly increased the prevalence of T2D, making its management a critical public health issue.

Aim: This review synthesizes evidence on the connection between obesity and T2D, evaluating the efficacy of structured management strategies—including lifestyle interventions, pharmacotherapy, and metabolic surgery—for prevention, treatment, and remission.

Methods: A comprehensive review of clinical trials, consensus guidelines (e.g., from the American Diabetes Association and the Second Diabetes Surgery Summit), and long-term studies was conducted. Data on weight loss, glycemic control (HbA1c), and diabetes remission rates across different interventions were analyzed.

Results: Intensive lifestyle intervention (ILI) can achieve >5% weight loss and reduce diabetes incidence by over 50%. Pharmacological agents like semaglutide and tirzepatide demonstrate 15-20% weight reduction. Metabolic surgery is the most effective intervention, with HbA1c reductions of ~2% and T2D remission rates of 30-60% over 1-5 years, proving cost-effective in the long term.

Conclusion: A multifaceted, guideline-directed approach is essential. ILI is the cornerstone, with pharmacotherapy and surgery providing powerful adjuncts for eligible patients. An interprofessional team is crucial for implementing these tiered strategies to reduce the burden of obesity-related diabetes.

Keywords: Obesity, Type 2 Diabetes, Insulin Resistance, Bariatric Surgery, GLP-1 Agonists, Lifestyle Intervention..

Introduction

Excess body weight and obesity represent critical determinants in the development and progression of type 2 diabetes (T2D). These conditions contribute to insulin resistance, dysregulated glucose metabolism, and increased risk for cardiovascular complications, making their management central to improving outcomes in patients with T2D. Clinicians are encouraged to adopt a comprehensive approach to obesity management in this population, following evidence-based recommendations outlined by professional organizations such as the American Diabetes Association and the American Obesity Association. These guidelines emphasize a structured framework that incorporates lifestyle interventions, pharmacological treatments, and, when indicated, surgical options. Lifestyle modification remains the foundational strategy, encompassing dietary adjustments, increased physical activity, and behavioral support to achieve sustained weight reduction and improved glycemic control. Pharmacological interventions are recommended when lifestyle measures alone fail to achieve therapeutic goals, with drug selection tailored to patient-specific factors, including comorbidities and treatment tolerance. In cases of severe obesity or insufficient response to conservative measures, metabolic and bariatric surgery is considered a viable and effective option for achieving substantial weight loss and ameliorating glycemic parameters [1][2].

The Second Diabetes Surgery Summit, convened in 2016 as an international consensus conference, addressed the evolving role of surgical intervention in managing patients with coexisting obesity and T2D. At this summit, experts formulated a detailed treatment algorithm to guide the selection of appropriate candidates for metabolic and bariatric procedures, taking into account both body mass index (BMI) thresholds and the presence of obesity-related complications [1][2]. The summit underscored the importance of individualized treatment planning, integrating patient preferences, risk profiles, and anticipated benefits of surgery. The consensus highlighted evidence demonstrating that certain bariatric procedures not only facilitate

*Corresponding author e-mail: alchaidibsm@gmail.com, (**Soliman Mohammed Alchaidib**)

Receive Date: 17 June 2025, Revise Date: 27 August 2025, Accept Date: 05 September 2025

DOI: 10.21608/EJCHEM.2025.395260.11921

©2025 National Information and Documentation Center (NIDOC)

significant weight reduction but also produce improvements in glycemic control that may exceed those achieved with intensive medical therapy alone. This recognition has led to the increasing incorporation of surgical options into standard T2D management protocols, particularly for patients with severe obesity or poorly controlled diabetes despite optimized medical care [1][2]. Current guidelines advocate a tiered approach to obesity management in T2D, where interventions escalate in intensity according to patient response and clinical risk. Initial strategies focus on lifestyle modification, emphasizing caloric restriction, macronutrient composition, and structured exercise programs. Behavioral support, including counseling and self-monitoring, enhances adherence and long-term success. Pharmacotherapy serves as an adjunct for patients who do not achieve sufficient weight loss or glycemic improvement through lifestyle changes alone. Medications are selected based on their efficacy, safety profile, and compatibility with existing comorbidities, reflecting a patient-centered approach to care. Surgical interventions are considered for individuals with higher BMI levels or when other therapies fail to achieve desired outcomes. Evidence from clinical trials and long-term follow-up studies has consistently shown that bariatric procedures can lead to durable weight loss, improved insulin sensitivity, and reductions in diabetes-related complications.

The integration of metabolic and bariatric surgery into T2D management requires careful evaluation of patient suitability, including assessment of cardiovascular risk, nutritional status, and psychosocial readiness for surgery. Multidisciplinary teams, comprising endocrinologists, surgeons, dietitians, and mental health professionals, play a critical role in optimizing perioperative care and long-term outcomes. Postoperative monitoring focuses on glycemic control, nutritional supplementation, and the prevention of surgical complications, with ongoing support to maintain lifestyle modifications and prevent weight regain. The Second Diabetes Surgery Summit emphasized that, while surgery is not appropriate for all patients, it represents a powerful tool in the therapeutic arsenal for managing obesity-related diabetes, particularly for those with severe disease burden [1][2]. In conclusion, obesity remains a principal modifiable risk factor for type 2 diabetes, and its management requires a multifaceted, guideline-directed approach. Lifestyle interventions constitute the cornerstone of therapy, supported by pharmacological options when necessary. For select patients, metabolic and bariatric surgery offers a highly effective modality that can produce substantial and sustained improvements in both weight and glycemic control. Consensus guidelines, such as those developed at the Second Diabetes Surgery Summit, provide structured algorithms to guide clinicians in tailoring interventions based on individual patient characteristics, risk profiles, and anticipated benefits [1][2]. The implementation of these strategies in clinical practice has the potential to significantly reduce the burden of obesity-related diabetes and improve long-term patient outcomes [1][2].

Issues of Concern

The relationship between obesity and type 2 diabetes (T2D) is well established, with body mass index (BMI) serving as a key determinant of disease risk. Epidemiological data indicate that the lifetime risk of developing diabetes rises sharply as BMI increases. In men aged 18 or older, this risk escalates from 7% at a BMI below 18.5 kg/m² to 70% at a BMI exceeding 35 kg/m². Women demonstrate a similar trend, with risk increasing from 12% to 74% across the same BMI spectrum [3]. This marked association between elevated BMI and T2D has led to recommendations for universal diabetes screening among patients with obesity. Effective management of obesity is crucial both for preventing the onset of T2D and for optimizing treatment outcomes in those already affected. Evidence demonstrates that weight reduction in at-risk populations significantly lowers the incidence of diabetes. For instance, lifestyle interventions aimed at achieving modest weight loss, defined as 5% to 10% of baseline body weight, combined with at least 150 minutes of physical activity per week, have been shown to reduce diabetes incidence by over 50% [4].



Figure 1: Classification of patients with obesity and diabetes type-2.

Bariatric surgery also presents a highly effective intervention in reducing the incidence of T2D. Long-term studies report a fivefold reduction in diabetes onset over seven years following surgical weight loss procedures [5]. Weight reduction not only serves a preventive role but also contributes to the management of existing T2D. Glycemic control improves proportionally with weight loss, with some patients achieving complete remission of diabetes [6]. Consequently, treatment strategies for T2D are structured in a stepwise manner, beginning with lifestyle management, progressing to pharmacological therapy, and considering surgical interventions when medically indicated. BMI remains the most widely utilized metric for categorizing body weight. It is calculated by dividing a person's weight in kilograms by the square of their height in meters (kg/m^2). BMI is used to classify individuals into distinct categories: underweight (<18.5 kg/m^2), healthy weight (18.5–24.9 kg/m^2, 18.5–22.9 kg/m^2 for Asian populations), overweight (25–29.9 kg/m^2, 23–27.4 kg/m^2 for Asian populations), obese class 1 (30–34.9 kg/m^2, 27.5–32.4 kg/m^2 for Asian populations), obese class 2 (35–39.9 kg/m^2, 32.5–37.4 kg/m^2 for Asian populations), and obese class 3 (≥40 kg/m^2, ≥37.5 kg/m^2 for Asian populations). Adjusted BMI thresholds for Asian populations reflect their higher percentage of body fat and the increased risk of T2D at lower BMI levels. These adjustments have been widely adopted by international organizations to improve the accuracy of obesity assessment and to guide appropriate intervention strategies in Asian populations [7].

Table 1: BMI Classification and Corresponding Treatment Recommendations

BMI Category (kg/m^2)	Standard Population	Asian Population	Recommended Treatment Strategy
Overweight	25.0 – 29.9	23.0 – 27.4	**Lifestyle Modification:** First-line intervention with diet and exercise.
Obesity Class I	30.0 – 34.9	27.5 – 32.4	**Lifestyle + Pharmacotherapy:** Consider adding FDA-approved weight loss medications, especially with weight-related comorbidities (e.g., T2D).
Obesity Class II	35.0 – 39.9	32.5 – 37.4	**Lifestyle + Pharmacotherapy/Surgery:** Strong candidate for pharmacotherapy. Surgery indicated, especially with comorbidities like uncontrolled T2D.
Obesity Class III	≥ 40.0	≥ 37.5	**Metabolic Surgery:** First-line consideration for eligible patients due to high efficacy. Pharmacotherapy is an alternative or

Mechanism, Chemistry, Pathophysiology, and Signaling Pathways:

Obesity and type 2 diabetes mellitus (T2DM) are closely interconnected metabolic disorders, with a complex relationship driven by shared pathophysiological mechanisms, particularly insulin resistance and β-cell dysfunction. Understanding the mechanism, pathophysiology, and signaling pathways underlying this connection provides key insights into disease progression. Obesity, especially characterized by excess abdominal and visceral adipose tissue, leads to metabolic disturbances central to diabetes development. Adipose tissue in obesity exceeds its normal storage capacity, resulting in increased lipolysis and release of elevated free fatty acids (FFAs). These FFAs induce lipotoxicity, causing oxidative and endoplasmic reticulum stress in insulin-responsive tissues such as liver, muscle, and adipose tissue as well as pancreatic β-cells. This stress impairs insulin receptor signaling, leading to systemic insulin resistance—a hallmark defect in T2DM. In muscle and liver, insulin resistance reduces glucose uptake and promotes inappropriate hepatic glucose production (gluconeogenesis), resulting in chronic hyperglycemia [7].

Obesity also provokes a pro-inflammatory state. Enlarged adipocytes secrete inflammatory adipokines such as TNF-α, IL-6, and resistin, while attracting macrophages into adipose tissue. These immune cells release cytokines that exacerbate inflammation and further impair insulin signaling. This adipose tissue inflammation is a key driver of peripheral insulin resistance. Simultaneously, lipotoxicity and inflammatory mediators impair β-cell function and promote β-cell apoptosis, decreasing insulin secretion capacity and leading to β-cell exhaustion. Thus, obesity initiates a vicious cycle where insulin resistance increases the demand on β-cells, progressively causing their dysfunction and ultimately insufficient insulin secretion. Several signaling pathways mediate the pathophysiological link between obesity and diabetes. Key pathways include:

- The PI3K/AKT pathway: Crucial for insulin signaling, this pathway becomes impaired due to FFAs and inflammatory cytokines, leading to reduced glucose uptake and glycogen synthesis in muscle and liver, driving insulin resistance.
- AMP-activated protein kinase (AMPK) pathway: Normally promotes energy balance by stimulating glucose uptake and fatty acid oxidation; however, obesity decreases AMPK activity, contributing to metabolic dysregulation.
- JAK/STAT and MAPK pathways: Activated by inflammatory cytokines from adipose tissue macrophages, these pathways promote inflammation-induced insulin resistance.
- TGF-β and Wnt/β-catenin signaling: Involved in adipogenesis and fibrosis, modulating adipose tissue dysfunction and systemic insulin sensitivity.

- Endoplasmic reticulum stress and oxidative stress signaling: Result from nutrient excess in obesity, further disrupting insulin receptor signaling and β-cell function.

Collectively, these pathways contribute to the metabolic derangements seen in obesity-induced insulin resistance and β-cell failure. Nutrient excess leads to activation of serine/threonine kinases that phosphorylate insulin receptor substrates on inhibitory sites, dampening the insulin signal. Concurrently, obesity-associated inflammation and mitochondrial dysfunction further impair insulin action. The pancreatic β-cells face increased secretory demand to compensate for insulin resistance, but chronic lipotoxic and inflammatory stress causes β-cell dysfunction and apoptosis, culminating in hyperglycemia and diabetes onset. In summary, the connection between obesity and diabetes involves a multifaceted interplay of increased free fatty acids, inflammatory adipokines, and dysfunctional cellular signaling pathways. These factors induce insulin resistance in peripheral tissues and progressive pancreatic β-cell failure. Understanding these mechanisms and pathways highlights potential therapeutic targets to intercept the progression of diabetes in obese individuals and emphasizes the importance of managing obesity to prevent T2DM [7]. This comprehensive mechanistic and signaling pathway overview underscores obesity as a principal driver of diabetes pathophysiology through metabolic, inflammatory, and cellular stress responses converging on impaired insulin action and secretion.

Lifestyle Management

Obesity is a chronic condition that substantially increases the risk for T2D. For patients diagnosed with overweight or obesity alongside T2D, intensive lifestyle interventions form the cornerstone of treatment. Comprehensive lifestyle management encompasses several components, including patient self-management education, nutritional counseling, structured physical activity, psychosocial support when indicated, and smoking cessation for individuals who smoke [8]. Patient education plays a pivotal role in enhancing understanding of chronic disease management, improving adherence to therapeutic regimens, and facilitating effective self-monitoring. Education is initiated at the time of diabetes diagnosis, reinforced annually, and provided as needed in response to the emergence of complications [9]. Effective patient education relies on an interprofessional approach, with nurses, dietitians, primary care physicians, and specialists contributing to the learning process. Methods such as motivational interviewing, visual aids, informational handouts, and electronic resources enhance patient engagement and understanding.

The primary objective of lifestyle modification is to achieve at least a 5% reduction in body weight, a threshold associated with clinically meaningful health benefits [10]. Evidence from the Look AHEAD trial demonstrates that intensive lifestyle intervention (ILI) can produce sustained weight loss greater than 5% in over half of participants, with 27% achieving weight reduction exceeding 10% at eight years [11]. Individuals participating in ILI required fewer medications for diabetes, hypertension, and lipid disorders, highlighting the broader metabolic benefits of weight loss. Achieving such weight loss typically requires a daily calorie deficit of 500 to 750 kcal, corresponding to daily intake goals of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men. While meal replacement strategies may facilitate adherence to these caloric targets, they are generally not suitable for long-term use. More sustainable dietary approaches include the DASH (Dietary Approaches to Stop Hypertension) diet and the Mediterranean diet, which have demonstrated effectiveness in supporting weight reduction while maintaining nutritional adequacy [12][13].

Intermittent fasting approaches have also been explored as potential strategies for weight loss. Evidence indicates that modified alternate-day fasting and the 5:2 diet are effective in achieving weight reductions exceeding 5%, providing alternative options for patients unable to adhere to continuous caloric restriction [14]. Dietary plans should be individualized to align with the patient's cultural preferences, food availability, and other practical considerations such as hunger cues and access to healthy food options. Counseling sessions targeting nutrition, physical activity, and behavioral goals are essential components of ILI and should be accessible to all patients. Standard ILI protocols typically include more than 16 sessions over six months, with ongoing monthly follow-ups for individuals who achieve target weight loss after the first year. However, delivering this level of intensive support may pose challenges in primary care due to limitations in resources and financial feasibility. Physical activity represents another critical element of lifestyle management for individuals with obesity and T2D. Patients should be encouraged to gradually increase their exercise levels, aiming for at least 150 minutes of moderate-intensity aerobic activity weekly. Optimal exercise regimens combine aerobic workouts with two to three sessions of resistance training each week. Consistent activity, with no more than two consecutive days without exercise, helps to improve insulin sensitivity and reduce the risk of glycemic deterioration [15].

Psychosocial factors are closely intertwined with obesity and T2D, necessitating regular screening for mood disorders and other mental health conditions. Addressing these comorbidities can enhance adherence to lifestyle interventions, optimize treatment outcomes, and improve overall quality of life [16][17]. In addition, clinicians should routinely assess tobacco use among adolescents and adults with obesity and diabetes, including the use of electronic cigarettes. Smoking is associated with heightened insulin resistance and an increased risk of developing diabetes [18]. Effective management includes counseling and, when appropriate, pharmacological interventions to facilitate smoking cessation, contributing to improved metabolic and cardiovascular outcomes. In summary, obesity represents a major modifiable risk factor for T2D, and its management is essential for both prevention and treatment. Intensive lifestyle interventions, encompassing dietary modification, structured physical activity, psychosocial support, patient education, and smoking cessation, are foundational strategies. Weight loss of 5% or more is associated with significant improvements in glycemic control and reductions in comorbid conditions. Evidence from clinical trials, including the Look AHEAD study, underscores the effectiveness of structured programs that integrate dietary, behavioral, and exercise components. Long-term adherence and individualized approaches are essential to achieving sustained benefits, and clinicians must address psychosocial and behavioral factors to optimize outcomes. Comprehensive lifestyle management, combined with pharmacological and surgical interventions as indicated, forms the basis of evidence-based care for patients with obesity and T2D, reducing disease burden and improving overall health.

Medical Evaluation and Treatment

When lifestyle modifications fail to achieve sufficient weight loss, clinicians must conduct a thorough medical evaluation to identify contributing factors. This evaluation should include a detailed review of the patient's medication history, as several commonly prescribed drugs may promote weight gain. These obesogenic medications include thiazolidinediones, beta-blockers, sulfonylureas, insulin, antipsychotics, antidepressants, corticosteroids, and gabapentin. Understanding these factors is critical to developing an effective and individualized treatment plan for patients with obesity and type 2 diabetes (T2D) (see Image. A Schematic Overview of Treatment Options for Type 2 Diabetes and Obesity). Pharmacotherapy is recommended as an adjunct to intensive lifestyle intervention (ILI) for patients with a body mass index (BMI) above 30 kg/m² (or above 25 kg/m² for Asian populations) or for individuals with a BMI exceeding 27 kg/m² (or above 23 kg/m² for Asians) who present with weight-related comorbidities such as hypertension, dyslipidemia, T2D, or obstructive sleep apnea [19]. The introduction of pharmacologic therapy requires close monitoring to evaluate both efficacy and safety. Patients who achieve at least 5% weight reduction within the first 12 weeks are considered early responders and are more likely to attain sustained long-term weight loss. Most weight loss medications are designed for chronic administration. While initial studies focused on short-term efficacy, substantial evidence over the past two decades has demonstrated the benefits of long-term pharmacological therapy. Exceptions include phentermine, which the U.S. Food and Drug Administration (FDA) has approved solely for short-term use (<12 weeks) due to potential abuse risks.

The FDA has approved several medications for long-term management of obesity and T2D. Among these, phentermine-topiramate extended-release represents a combination therapy approved in 2012. Clinical evidence, including results from the SEQUEL trial, demonstrated an average weight loss of approximately 10% in patients receiving the combination, compared with less than 2% in the placebo group [20]. This medication is effective across a spectrum of obesity, including patients with a BMI greater than 45 kg/m². The initial dosage consists of 3.75 mg phentermine combined with 23 mg of extended-release topiramate (3.75 mg/23 mg), with titration up to 15 mg/92 mg over two-week intervals based on tolerance. Common adverse effects include insomnia, elevated blood pressure, dry mouth, and paresthesias. Concomitant use with monoamine oxidase inhibitors is contraindicated. Because phentermine-topiramate increases the risk of congenital malformations such as cleft lip and cleft palate, clinicians must confirm that women of childbearing potential are not pregnant and are using effective contraception prior to initiation. Other FDA-approved agents include liraglutide, semaglutide, and tirzepatide. Liraglutide and semaglutide function as glucagon-like peptide-1 (GLP-1) receptor agonists, while tirzepatide combines GLP-1 receptor agonism with glucose-dependent insulinotropic polypeptide (GIP) receptor activity. Although originally approved for T2D management, these medications have demonstrated significant weight reduction. Mechanisms of action include enhanced insulin secretion, improved insulin sensitivity, glucagon suppression, delayed gastric emptying, and increased satiety through central nervous system pathways. Despite these benefits, high costs and limited insurance coverage may limit patient access [20].

Liraglutide, as evaluated in the SCALE trial, achieved an additional approximate 5% weight loss relative to placebo [21]. The medication is administered subcutaneously, beginning at 0.6 mg daily and titrated weekly to a maximum of 3 mg daily. Gastrointestinal side effects, primarily nausea, are the most frequently reported adverse events. Semaglutide, studied in the STEP clinical trials, demonstrated even greater efficacy, with participants achieving 15% to 16% weight reduction by week 68 [22]. The initial dose is 0.25 mg subcutaneously once weekly, with dose escalation every four weeks to a maximum of 2.4 mg weekly. The data indicate that semaglutide can produce more substantial weight loss than liraglutide. Tirzepatide has been studied in the SURMOUNT-2 trial for individuals with T2D and obesity defined as a BMI above 30 kg/m² or above 27 kg/m² with weight-related comorbidities [23]. Its dual mechanism combining GLP-1 and GIP receptor agonism yields superior efficacy in glycemic control and weight reduction compared with GLP-1 receptor agonists alone, with weight reductions reaching approximately 20% at the maximum weekly dose of 15 mg subcutaneously. The Phase III SURPASS trials further validated tirzepatide's effectiveness, demonstrating superiority over dulaglutide (0.75 mg) and semaglutide (1 mg) when used as monotherapy or adjunctive therapy to oral glucose-lowering agents or insulin [24]. The SURMOUNT-5 trial extended these findings to patients with obesity but without diabetes, confirming that tirzepatide produced greater weight loss than semaglutide in this population [25].

The introduction of pharmacotherapy for obesity in T2D emphasizes the importance of individualized treatment selection, careful monitoring, and patient education regarding expected outcomes and potential side effects. The clinical objective is to achieve sustained weight reduction that translates into improved glycemic control, decreased medication requirements, and reduced incidence of comorbid conditions. Clinicians must assess patient adherence, tolerance, and response to therapy, adjusting as necessary to optimize outcomes. Long-term therapy may require ongoing support from a multidisciplinary team, including endocrinologists, primary care physicians, pharmacists, and dietitians. Overall, medical evaluation and pharmacologic treatment provide a structured approach for patients who do not achieve sufficient weight loss through lifestyle interventions alone. Pharmacotherapy, particularly with FDA-approved agents, can facilitate significant and clinically meaningful reductions in body weight, improve metabolic parameters, and contribute to T2D management. Medications such as phentermine-topiramate, liraglutide, semaglutide, and tirzepatide demonstrate varying mechanisms of action and degrees of efficacy, offering clinicians multiple options to tailor therapy to individual patient profiles. By integrating these medications with ongoing lifestyle interventions, healthcare providers can maximize the likelihood of achieving durable weight loss and enhanced metabolic outcomes.

Naltrexone-bupropion Sustained Release

Naltrexone-bupropion sustained release is a combination pharmacotherapy that facilitates weight reduction through complementary mechanisms of action. Naltrexone functions as an opioid antagonist, while bupropion is classified as an antidepressant with dopaminergic and noradrenergic activity. Together, these agents target central pathways regulating appetite

and reward, thereby decreasing food intake and promoting satiety. Administration of this combination requires gradual titration to reduce the likelihood of intolerance and adverse reactions. The initial dose consists of one tablet of 8 mg/90 mg daily, which may be increased progressively to a maximum of two tablets of 16 mg/180 mg twice daily as tolerated by the patient. Contraindications include uncontrolled hypertension, seizure disorders, and concurrent long-term opioid therapy, reflecting the need for careful patient selection and monitoring [26].

Orlistat

Orlistat represents another pharmacological option for weight management, functioning as a pancreatic lipase inhibitor that limits intestinal fat absorption. It is typically administered as a 60-mg tablet taken three times daily with meals. Evidence from the XENDOS trial demonstrated that orlistat treatment produced approximately 5% weight loss in study participants [27]. However, adverse gastrointestinal effects, including flatulence, abdominal discomfort, and fecal urgency, often limit tolerability and adherence. Long-term use of orlistat may also result in malabsorption of fat-soluble vitamins, while increasing the risk of gallstone formation and kidney stone development. These considerations highlight the importance of dietary counseling and monitoring when prescribing orlistat, particularly in patients at risk of nutritional deficiencies or gastrointestinal complications.

Surgical Treatment

For patients with suboptimal weight loss through lifestyle or pharmacological interventions, surgical management of obesity represents an effective therapeutic option, particularly when hyperglycemia remains uncontrolled. Surgical interventions are generally recommended for individuals with a BMI exceeding 40 kg/m², or for those with a BMI between 35 and 39.9 kg/m² who also have hyperglycemia, weight-related comorbidities, or difficulty achieving sustainable weight reduction. Emerging evidence, reviewed at the Second Diabetes Surgery Summit, supports considering surgical intervention even for patients with a BMI of 30 to 34.9 kg/m² in the presence of uncontrolled hyperglycemia [2]. Metabolic and bariatric surgery operates through structural and hormonal mechanisms to achieve substantial and sustained weight loss. Common surgical options include Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), laparoscopic adjustable gastric banding (LAGB), and biliopancreatic diversion with duodenal switch (BPD). Among these, RYGB and VSG are most frequently employed due to their robust long-term outcomes and favorable safety profiles. While BPD demonstrates high efficacy in weight reduction, it is associated with increased surgical complications, whereas LAGB is recognized for safety but carries a higher likelihood of requiring revision or re-intervention [2].

The physiological mechanisms underlying the effectiveness of bariatric surgery include alteration of gastrointestinal anatomy to promote early satiety, reduction of nutrient absorptive surface area, and modulation of hormones involved in glucose regulation. Surgery positively impacts intestinal glucose metabolism, pancreatic islet hormone activity, nutrient sensing, and bile acid dynamics [28][29][30][31]. RYGB, in particular, enhances insulin sensitivity, increases adiponectin levels, and upregulates muscle insulin receptors, thereby improving fatty acid metabolism and reducing lipid accumulation in muscle and liver tissue. These metabolic adaptations contribute to improved insulin action and glycemic control [28]. Additionally, RYGB has been shown to augment insulin secretion through both glucose-dependent and glucose-independent pathways, reflecting the profound endocrine effects of bariatric surgery [29]. Because of these extensive metabolic consequences, bariatric procedures are frequently described as metabolic surgery.

Numerous studies have confirmed the role of bariatric surgery in controlling and, in some cases, preventing T2D [32][33][34][35][36]. While most randomized controlled trials comparing surgical approaches with intensive lifestyle interventions have follow-up periods of one to two years, several studies have extended observations to five years. Across trials, patients undergoing surgery experienced an average hemoglobinA1c (HbA1c) reduction of approximately 2%, compared to 0.5% in patients receiving conventional treatment. Many surgical patients achieved an HbA1c of roughly 6%, with T2D remission—defined as nondiabetic HbA1c without pharmacotherapy—occurring in the majority. Sustained remission rates range from 30% to 60% over follow-up periods of one to five years; however, the durability of benefits may decline in patients with poor preoperative glycemic control, longer diabetes duration, or insulin use [38]. Relapse of T2D is reported in 35% to 50% of patients, though RYGB has been associated with a median disease-free period of 8.3 years. Even when complete remission is not achieved, surgical intervention consistently improves glycemic control and clinical outcomes. Long-term observational data over 10 to 20 years indicate significantly reduced complications and higher remission rates in surgical cohorts [39].

Among surgical modalities, RYGB and BPD achieve the most pronounced reductions in HbA1c and BMI. Research focusing on patients with a BMI of 30 to 35 kg/m² and uncontrolled T2D consistently demonstrates improved glycemic control and increased remission rates following surgery [35][40][41][34]. LAGB has also shown favorable outcomes in individuals with T2D and BMI between 25 and 30 kg/m² [42]. Economic evaluations of bariatric surgery indicate cost-effectiveness in the management of T2D. The cost per quality-adjusted life-year (QALY) for metabolic surgery generally ranges from $3,200 to $6,300, substantially below the conventional $50,000 threshold for nonsurgical interventions [2]. The 15-year follow-up of the Swedish Obese Subjects (SOS) study revealed no significant differences in total healthcare costs between patients treated surgically and those receiving conventional care [43]. Safety outcomes have improved markedly over the past two decades, with mortality rates ranging from 0.1% to 0.5%. Nonetheless, thorough patient counseling regarding surgical risks and complications remains essential. Reoperation and readmission rates vary by procedure, with RYGB reporting 2.5% and 5.1%, VSG 0.6% and 5.5%, and LAGB 0.6% and 2%, respectively [45]. Long-term follow-up indicates that LAGB has the highest rates of device removal or revision, while VSG has gained popularity as surgical expertise has increased. BPD remains the most complex procedure, associated with higher morbidity and mortality risks. Postoperative care must include monitoring for nutritional deficiencies, such as iron deficiency anemia, hypoglycemia, and bone demineralization, in addition to vigilance for short-term and long-term surgical complications.

In conclusion, pharmacological and surgical interventions offer effective strategies for the management of obesity and T2D, particularly in patients who fail to achieve adequate results from lifestyle modification alone. Naltrexone-bupropion and orlistat provide viable medical options, each with specific mechanisms of action, dosing protocols, and safety considerations. For individuals with severe obesity or uncontrolled hyperglycemia, metabolic and bariatric surgery achieves profound weight loss and improvements in glycemic control, with long-term data demonstrating disease remission, reduced complications, and cost-effectiveness. Clinicians must tailor interventions to individual patient characteristics, comorbidities, and risk profiles, ensuring careful monitoring and ongoing support to optimize outcomes [42][43][44][45].

Table 2: Efficacy of Primary Treatment Modalities for Obesity and Type 2 Diabetes

Intervention Category	Specific Example	Average Weight Loss	Impact on HbA1c	Key Evidence
Lifestyle Modification	Intensive Lifestyle Intervention (ILI)	>5% at 8 years	Improves glycemic control	Look AHEAD Trial: >50% reduction in diabetes incidence
Pharmacotherapy	Semaglutide (GLP-1 RA)	15-16% at 68 weeks	Significant reduction	STEP Trials
	Tirzepatide (GIP/GLP-1 RA)	~20%	Superior to other GLP-1 RAs	SURMOUNT & SURPASS Trials
	Phentermine-Topiramate ER	~10%	Improves glycemic control	SEQUEL Trial
	Liraglutide (GLP-1 RA)	~5% (vs. placebo)	Significant reduction	SCALE Trial
Metabolic Surgery	Roux-en-Y Gastric Bypass (RYGB)	Most pronounced	Reduction of ~2%	Multiple RCTs; durable remission
	Sleeve Gastrectomy (VSG)	Substantial	Reduction of ~2%	

Clinical Significance

Obesity represents a critical determinant in the development and progression of type 2 diabetes (T2D), and its management is closely linked to healthcare quality outcomes. Numerous metrics used to assess healthcare quality emphasize the effectiveness of both prevention and treatment strategies for diabetes, highlighting the need for early identification of at-risk populations. Screening patients with obesity at an early stage allows clinicians to implement intensive interventions that may prevent disease onset or achieve significant long-term improvements in glycemic control. Evidence indicates that prompt and targeted management can, in some cases, lead to remission of T2D, reducing the need for complex therapeutic regimens and mitigating disease burden. Tight glycemic control is essential to minimizing the risk of acute and chronic complications associated with diabetes. Effective management reduces the incidence of life-threatening conditions such as diabetic ketoacidosis and mitigates risks associated with chronic hyperglycemia, including diabetic foot ulcers, infections of soft tissues, osteomyelitis, and the potential need for limb amputations. Furthermore, rigorous control of hemoglobinA1c (HbA1c) levels contributes to the reduction of macrovascular and microvascular complications. Lowering HbA1c has been shown to decrease the risk of coronary artery disease, which is a leading cause of mortality among patients with T2D, as well as chronic kidney disease, which can progress to end-stage renal failure if left unaddressed. The clinical significance of obesity management in T2D extends beyond individual patient outcomes to broader public health and economic implications. By preventing the onset of diabetes and limiting complications, early and effective interventions reduce hospitalizations, healthcare costs, and long-term disability. Consequently, integrating obesity screening and intensive diabetes management into routine clinical practice is essential to improving both patient-level outcomes and system-wide healthcare quality [2][3].

Enhancing Healthcare Team Outcomes

Diabetes is a chronic and debilitating disease, and the rising prevalence of obesity continues to drive its increasing incidence worldwide. Effective management of obesity is essential not only for the prevention of type 2 diabetes (T2D) but also for optimizing treatment outcomes in patients already diagnosed. Achieving these objectives requires a coordinated, interprofessional approach, where healthcare providers collaborate to deliver comprehensive care. Early identification of patients with obesity in primary care settings constitutes a critical first step in ensuring favorable clinical outcomes, as it allows timely intervention before metabolic complications progress. Nurses frequently serve as the first point of patient contact and play a central role in evaluating anthropometric measures, including height, weight, and body mass index (BMI). Accurate

measurement and consistent documentation are essential for monitoring progress and informing treatment strategies. Beyond these measurements, nurses are tasked with assessing baseline dietary patterns and physical activity levels and revisiting these factors at each follow-up appointment. Patients with elevated BMI values should be educated regarding their weight classification and the associated risks for T2D. Clinicians should work with patients to set individualized weight loss targets, with a recommended goal of at least 10% reduction in body weight to achieve significant metabolic improvements. Intensive lifestyle interventions, combined with pharmacotherapy when indicated, should be implemented in line with current evidence-based clinical guidelines.

Suboptimal glycemic control and insufficient weight reduction, defined as less than 10%, must be evaluated at every encounter. Persistent hyperglycemia or inadequate weight loss should prompt referral to specialists in obesity medicine or bariatric surgery. Multidisciplinary weight loss programs often involve close collaboration among physicians, surgeons, and other healthcare professionals. Obesity medicine specialists support patients in achieving target weight thresholds for surgical eligibility and provide critical postoperative care by monitoring for complications and reinforcing lifestyle modifications to maintain long-term weight loss. Even for patients ineligible for metabolic surgery due to advanced cardiac or pulmonary comorbidities, obesity medicine interventions can produce meaningful health improvements. Registered dietitians, nutritionists, and behavioral therapists are integral to the healthcare team, offering structured support for optimizing nutrition and physical activity. Leadership of these interprofessional teams may rotate among dietitians, therapists, nurses, physicians, or surgeons, depending on expertise and patient needs. Endocrinology consultations provide additional guidance for managing persistent hyperglycemia, while high-risk patients often require preoperative evaluation by cardiologists or pulmonologists. Surgical interventions should ideally occur in centers equipped with on-site cardiac and pulmonary critical care capabilities. Pharmacists contribute by adjusting medication regimens, particularly in the perioperative period, where weight-based dosing modifications are frequently necessary after metabolic procedures.

The anesthesia team is responsible for preoperative assessments and the management of perioperative and postoperative anesthetic events. Physical therapists assist in muscle strengthening and rehabilitation, enhancing postoperative recovery and promoting functional outcomes. Given the strong association between obesity and mental health disorders, including anxiety, depression, and body image disturbances, consultations with psychiatry or psychology specialists should be considered as needed to support patient well-being. Obesity and T2D are systemic, chronic conditions that demand a cohesive interprofessional approach for successful prevention and management. Coordinated efforts by healthcare professionals, including nurses, physicians, dietitians, surgeons, pharmacists, therapists, and mental health specialists, provide patients with the resources, guidance, and education necessary to make informed decisions about their care. Such collaboration improves patient adherence, supports long-term behavioral change, and enhances clinical outcomes, underscoring the importance of integrated care models in addressing the complex interplay of obesity and T2D.

Interprofessional Team Interventions

Interprofessional interventions play a central role in identifying type 2 diabetes (T2D) among patients with obesity. Healthcare providers must recognize medications that contribute to weight gain and consider safer alternatives to mitigate metabolic risk. Nurses are responsible for measuring and documenting body mass index (BMI) at each clinical encounter, alerting the provider when BMI exceeds 25 kg/m². Patients who meet this threshold and have not undergone previous testing should be screened for T2D. Primary care clinicians are responsible for initiating lifestyle interventions for all individuals with a BMI of 25 kg/m² or higher, with standard written guidance on diet and exercise reviewed consistently at follow-up visits. Clinicians support patients in establishing realistic and measurable weight loss objectives, targeting a BMI below 25 kg/m² or a reduction of 5% to 10% of baseline body weight. A BMI exceeding 30 kg/m² prompts consideration of intensive lifestyle interventions (ILI) in conjunction with pharmacological therapy to enhance weight reduction and metabolic outcomes. Registered dietitians and nutritionists provide critical support, offering patients the knowledge and skills to make informed dietary decisions that align with their health goals. The success of these interventions relies heavily on an interprofessional model of care, characterized by coordinated communication between primary care providers, endocrinologists, and other relevant specialists. When lifestyle interventions and pharmacotherapy fail to achieve adequate glycemic control and meaningful weight loss, timely referral to bariatric and metabolic surgeons is essential. Surgical evaluation ensures that patients receive comprehensive care and access to procedures that may provide durable improvements in both weight and diabetes management. Overall, the interprofessional approach integrates the expertise of nurses, allied health professionals, primary care clinicians, and surgical specialists to optimize outcomes for patients with obesity and T2D, ensuring interventions are timely, evidence-based, and patient-centered.

Interprofessional Team Monitoring

Effective management of patients with obesity and type 2 diabetes (T2D) requires continuous monitoring by an interprofessional healthcare team. Key metrics, including hemoglobinA1c (HbA1c), body weight, BMI, and adherence to lifestyle modifications, should be evaluated at every patient encounter. Clinicians provide education regarding potential medication-related adverse effects and make dose adjustments as necessary. Pharmacists reinforce this counseling, ensure proper medication reconciliation, and contribute to optimizing pharmacotherapy safety and effectiveness. Following metabolic surgery, patients necessitate heightened surveillance due to physiological changes and potential complications. Although many patients require fewer medications postoperatively because of improved metabolic control, the risk of hypoglycemia may increase. Nurses play a crucial role in identifying and documenting surgical complications, such as wound dehiscence, perforation, or signs of infection, and promptly alert the healthcare team for intervention. Dietitians and nutritionists assess for nutritional deficiencies, malabsorption syndromes, and other metabolic derangements. Preventive measures, including avoiding nonsteroidal anti-inflammatory drugs during the initial postoperative month, are emphasized to reduce the risk of erosion at anastomotic sites. Internal quality metrics are utilized to track surgical outcomes, including remission rates, procedural safety,

postoperative recovery, and long-term efficacy. Obesity significantly elevates the risk of T2D, cardiovascular disease, and multiple chronic conditions, making routine screening and early intervention critical. BMI remains the standard measure to quantify obesity severity, guiding the implementation of intensive lifestyle interventions (ILI) and pharmacological therapy, with a target of achieving at least 10% weight loss. Patients who fail to achieve sufficient weight reduction or glycemic control despite optimal medical management should be referred for bariatric surgery. Over the past two decades, surgical interventions have demonstrated increased safety and efficacy. Sustained postoperative monitoring by the interprofessional team ensures timely identification of complications, supports long-term adherence to dietary and lifestyle recommendations, and maximizes clinical outcomes, contributing to both improved patient safety and durable disease management.

Conclusion:

The intricate and well-established link between obesity and type 2 diabetes (T2D) necessitates a comprehensive and escalating management strategy. This review underscores that effective control of obesity is not merely adjunctive but central to both preventing T2D and achieving optimal glycemic outcomes in those already diagnosed. The pathophysiological cascade, initiated by visceral adiposity leading to lipotoxicity, chronic inflammation, and impaired insulin signaling, provides a clear mechanistic rationale for targeting weight loss as a primary therapeutic goal. The evidence conclusively supports a tiered treatment algorithm. Intensive Lifestyle Intervention (ILI) remains the indispensable foundation, capable of producing significant metabolic benefits with a modest 5-10% weight loss. For patients who do not achieve sufficient results with ILI alone, a new generation of pharmacotherapies, particularly GLP-1 receptor agonists and dual GIP/GLP-1 agonists like semaglutide and tirzepatide, offer unprecedented efficacy in weight reduction and glycemic control, revolutionizing medical management. For individuals with severe obesity or uncontrolled T2D, metabolic and bariatric surgery stands as the most potent intervention. Procedures such as Roux-en-Y Gastric Bypass and Sleeve Gastrectomy offer profound and durable weight loss, directly targeting the disease's pathophysiology by altering gut hormone secretion and nutrient sensing. The high rates of diabetes remission and dramatic reductions in long-term complications solidify its role not as a last resort but as a cost-effective standard of care for appropriate candidates. Ultimately, the successful implementation of these strategies hinges on an interprofessional, patient-centered approach. From nurses and primary care physicians conducting initial screening and education to dietitians, endocrinologists, surgeons, and mental health specialists providing specialized care, coordination is key. Continuous monitoring of weight, HbA1c, and nutritional status ensures long-term success and management of complications. By embracing this integrated model and leveraging the full spectrum of available interventions—lifestyle, pharmacological, and surgical—clinicians can significantly alter the disease course, reduce complications, and improve the quality of life for millions of patients with obesity and T2D.

References:

1. Cohen RV, Shikora S, Petry T, Caravatto PP, Le Roux CW. The Diabetes Surgery Summit II Guidelines: a Disease-Based Clinical Recommendation. Obes Surg. 2016 Aug;26(8):1989-91.
2. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE., Delegates of the 2nd Diabetes Surgery Summit. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016 Jun;39(6):861-77.
3. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007 Jun;30(6):1562-6.
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 07;346(6):393-403.
5. Booth H, Khan O, Prevost T, Reddy M, Dregan A, Charlton J, Ashworth M, Rudisill C, Littlejohns P, Gulliford MC. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol. 2014 Dec;2(12):963-8.
6. Kahan S, Fujioka K. Obesity Pharmacotherapy in Patients With Type 2 Diabetes. Diabetes Spectr. 2017 Nov;30(4):250-257.
7. Misra A. Ethnic-Specific Criteria for Classification of Body Mass Index: A Perspective for Asian Indians and American Diabetes Association Position Statement. Diabetes TechnolTher. 2015 Sep;17(9):667-71.
8. Powers MA, Bardsley JK, Cypress M, Funnell MM, Harms D, Hess-Fischl A, Hooks B, Isaacs D, Mandel ED, Maryniuk MD, Norton A, Rinker J, Siminerio LM, Uelmen S. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care. 2020 Jul;43(7):1636-1649.
9. American Diabetes Association. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: *Standards of Medical Care in Diabetes-2021*. Diabetes Care. 2021 Jan;44(Suppl 1):S53-S72.
10. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J AcadNutr Diet. 2015 Sep;115(9):1447-63.
11. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014 Jan;22(1):5-13.

12. Azadbakht L, Fard NR, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, Esmaillzadeh A, Willett WC. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011 Jan;34(1):55-7.
13. D'Innocenzo S, Biagi C, Lanari M. Obesity and the Mediterranean Diet: A Review of Evidence of the Role and Sustainability of the Mediterranean Diet. Nutrients. 2019 Jun 09;11(6)
14. Patikorn C, Roubal K, Veettil SK, Chandran V, Pham T, Lee YY, Giovannucci EL, Varady KA, Chaiyakunapruk N. Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials. JAMA Netw Open. 2021 Dec 01;4(12):e2139558.
15. Little JP, Gillen JB, Percival ME, Safdar A, Tarnopolsky MA, Punthakee Z, Jung ME, Gibala MJ. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J ApplPhysiol (1985). 2011 Dec;111(6):1554-60.
16. Kulzer B, Albus C, Herpertz S, Kruse J, Lange K, Lederbogen F, Petrak F. Psychosocial Factors and Diabetes. ExpClinEndocrinol Diabetes. 2023 Feb;131(1-02):94-109.
17. Annesi JJ. Moderation of Mood in the Transfer of Self-Regulation From an Exercise to an Eating Context: Short- and Long-Term Effects on Dietary Change and Obesity in Women. Int J Behav Med. 2019 Jun;26(3):323-328.
18. Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res. 2017 Jun;184:101-107.
19. Son JW, Kim S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes Metab J. 2020 Dec;44(6):802-818.
20. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J ClinNutr. 2012 Feb;95(2):297-308.
21. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA., NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015 Aug 18;314(7):687-99.
22. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF., STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.
23. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A., SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216.
24. France NL, Syed YY. Tirzepatide: A Review in Type 2 Diabetes. Drugs. 2024 Feb;84(2):227-238.
25. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP., SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 03;393(1):26-36.
26. Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P., AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022 Nov;163(5):1198-1225.
27. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61.
28. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009 Jun;150(6):2518-25.
29. Salehi M, Woods SC, D'Alessio DA. Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion. Obesity (Silver Spring). 2015 Oct;23(10):2046-52.
30. Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab. 2015 Aug 04;22(2):228-38.
31. Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012 Jun;18(6):950-5.
32. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012 Apr 26;366(17):1577-85.
33. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26;366(17):1567-76.
34. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013 Jun 05;309(21):2240-9.
35. Parikh M, Chung M, Sheth S, McMacken M, Zahra T, Saunders JK, Ude-Welcome A, Dunn V, Ogedegbe G, Schmidt AM, Pachter HL. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes

remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg. 2014 Oct;260(4):617-22; discussion 622-4.
36. Ding SA, Simonson DC, Wewalka M, Halperin F, Foster K, Goebel-Fabbri A, Hamdy O, Clancy K, Lautz D, Vernon A, Goldfine AB. Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial. J ClinEndocrinolMetab. 2015 Jul;100(7):2546-56.
37. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015 Sep 05;386(9997):964-73.
38. Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O'Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013 Jan;23(1):93-102.
39. Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014 Jun 11;311(22):2297-304.
40. Liang Z, Wu Q, Chen B, Yu P, Zhao H, Ouyang X. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res ClinPract. 2013 Jul;101(1):50-6.
41. Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, Toledo FG, Jakicic JM. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):707-15.
42. Wentworth JM, Playfair J, Laurie C, Ritchie ME, Brown WA, Burton P, Shaw JE, O'Brien PE. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014 Jul;2(7):545-52.
43. Keating C, Neovius M, Sjöholm K, Peltonen M, Narbro K, Eriksson JK, Sjöström L, Carlsson LM. Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2015 Nov;3(11):855-65.
44. Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/diabetes surgery? Diabetes ObesMetab. 2015 Feb;17(2):198-201.
45. Birkmeyer NJ, Dimick JB, Share D, Hawasli A, English WJ, Genaw J, Finks JF, Carlin AM, Birkmeyer JD., Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. JAMA. 2010 Jul 28;304(4):435-42.